ADV is a non-defective parvovirus (single stranded DNA virus), which causes a persistent infection in mink and a slowly progressive lymphoproliferative disease, characterised by plasmacytosis, hypergammaglobulinaemia and immune complex-mediated glomerulonephritis and arteritis.
Earlier vaccination efforts have failed so far, probably because the vaccines contained low amounts of inactivated virus. In one report (Porter et al., J. Immunol. 72, 1, 1972) vaccination was even described to increase the severity of disease.
We have produced relatively large amounts of ADV structural proteins in a recombinant baculovirus expression system and used them in various vaccines. The results of these ongoing studies will be reported. A transmissible gastroenteritis (TGE) coronavirus mutant (188-SG), selected as attenuated and resistant to acidity and proteases of the digestive tract of adult pigs, was used as vaccine ("Nouzilly strain") in sows to protect suckling piglets against a challenge exposure carried out with a highly virulent TGEV strain. The pregnant sows were immunized once (42-49 days before farrowing) or twice (42-49 and 7-15 days before farrowing) by the oral, intramuscular or conjunctival route with the 188-SG strain. Sows exposed to virulent TGEV in the field and experimentally infected sows (two oral inoculations during pregnancy) were used as positive controls leading to high protection. The neutralizing antibody response to vaccination and/or infection was studied in serum and milk. No protection against mortality was observed in the litters of (1) the nine seronegative, susceptible sows, with piglet mortality of 65/70, (2) the seven once orally vaccinated sows, with mortality of 44/54, (3) the seven sows vaccinated twice by the conjunctival route, with mortality of 55/76. Moderate protection was observed in (1) the eight sows vaccinated intramuscularly twice with piglet mortality of 36/90, (2) the seven orally and intramuscularly vaccinated sows with piglet mortality of 31/51. In contrast, improved protection was observed in (1) the 10 sows vaccinated twice orally, with piglet mortality of 23/95, (2) the four naturally infected sows with piglet mortality of 6/41, (3) the six sows experimentally infected with virulent TGEV with piglet mortality of 1/59. No correlation was found between neutralizing antibodies titers in serum and milk and protection rate of the piglets. The results indit~ate that relative protective lactogenic immunity against TGEV is induced only by repeated ingestion of the attenuated 188-SG strain of TGEV. In three important species of food animals the adjuvant effect of particulate fl-D-glucan isolated from Saccharomyces cerevisiae was studied. All experimental groups were injected alternatively with a T-dependent (SRBC, BSA, HSA) or a T-independent antigen (Brucella abortus, tetanus toxoid) simultaneously rith glucan in the dose of 10 mg/kg 1 i.m. The antibody response to these antigens was significantly stimulated in all species by 197 up to 647 % in comparison with controls immunised without glucan. In chickens only, the increase of antibody production to Brucella was not significant but a stimulation of natural antibodies and breed differences in the immune response were seen. Foot-and-mouth disease is one of the most economically important disease among meat-producing biungulated species.
In contrast to natural infection, current foot-and-mouth disease virus (FMDV) vaccines prepared with inactivated virus and adjuvants elicited shortlive protection.
The immunomodulating effect on FMDV vaccines of an extract of the cell wall of Mycobacterium sp. (WSF), Avridine and lypopolysaccharide of Brucella ovis (LPS) was tested in a murine model.
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The duration of immunity, protection, stimulation of immunocompetent cells acting on the long lasting secondary response and immunoglobulin (Ig) isotypes were examined.
The incorporation of any single immunomodulator into aqueous and oil vaccines induced a high and long-lasting specific antibody response. The neutralizing titres and protection were significantly higher than those observed in animals immunized control vaccines. Data collected from repopulation assays indicate that the immunomodulators used participate in the activation of immune cell populations involved in long-lasting memory. This results in an efficient B-cell secondary response even in the absence of T cells, which are necessary for the stimulation effect of the immunomodulators in donor mice.
Avridine, WSF and LPS stimulated the IgG1, 2a and 2b production, which was correlated with improvement of the protection induced by these products. Seven groups of 5 calves were vaccinated with various preparations of P. haemo?ytica. Four groups received purified capsular polysaccharide (CPS) alone or in combination with other antigens. Of 25 calves which received capsule in any form, 36% (9 calves) exhibited clinical signs of systemic anaphylaxis immediately following vaccination. All calves had evidence of serum IgM, IgG, and IgG2 to CPS by enzyme immunoassay (EIA), but an IgE response was not detectable by EIA. However, on IgE specific Western immunoblot, the calves exhibiting anaphylaxis had a strong response to a high molecular weight component of the purified preparation, which was only weakly reactive in the non-anaphylactic calves. These findings suggest that although immunogenic, the purified CPS ofP. haemotytica AI is a poor vaccine candidate. An intrinsic property of several common adjuvants for veterinary vaccines (e. g. IFA, CFA, Quill A, Dextran sulphate) is their ability to promote the synthesis of interferon (IFN)-7 (1). In contrast, aqueous antigen and alum do not cause release of T-IFN from sheep leucocytes in vivo or in vitro in primary or secondary responses (1). Further investigation of the effect of IFN-7 on sheep immune responses to ovalbumin and parasite antigens was undertaken by administration in vivo of monoclonal antibodies to bovine IFN-7 at various intervals before and after the inoculation of adjuvanted ovalbumin. Immune responses were monitored in efferent lymph from the prefemoral lymph node. The a-7-IFN MAb suppressed the appearance of lymph-borne 7-IFN whereas an irrelevant MAb did not. However, the immune response (lymphoblasts, antibody titre) were not significantly affected. The synthetic lipopeptides Pam3Cys-OH, Pam3Cys-Ser-Ser-Asn-Ala and the lipohexapeptide Pam3Cys-Ser-(Lys)4 (Pam3Cys = tripalmitoyl-S-glycerylcysteine) which were described as non-toxic adjuvants were compared to Freund's complete adjuvant (FCA) immunizing BALB/c mice with the hapten MATP (4-Amino-l,2,2-trimethylphenylphosphonate) coupled to human serum albumin (HSA).
While Pam3Cys-OH induced no increase in specific serum antibodies and Pam3-Cys-Ser-Ser-Asn-Ala provoked only marginal titers, we found an excellent immunostimulation with the synthetic lipopeptide Pam3Cys-Ser-(Lys)4 which was very close to the immunoenhancing effect of FCA. With regard to the production of monoclonai antibodies we studied the influence of these adjuvants on the affinity of antibody subpopulations with a new method to investigate affinity distribution.
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The need of potent adjuvants to improve the immune response to modern antigens is in constant increase. Oil compositions are recognized as being amoung the most powerful adjuvants and of quite general efficiency.
Freund's adjuvants, based on mineral oil, with or without mycobacteria, are still reference adjuvants in many laboratory experiments. Their use in flied vaccinations is however banned because of the viscosity of the obtained vaccines and of the local reactions at the injection site.
In order to improve safety and to minimize the residues in the injected animals, new adjuvants based on metabolizable oils or with low amount of oil have now been designed.
Safety data and vaccination results, either in Laboratory animals or in domestic food animals are presented on several new products:
MONTANIDE ISA 763 and MONTANIDE ISA 708 are adjuvants without mineral oil, designed for fluid W/O vaccines. They are based on different pharmaceutical grade metabolizable oils.
MONTANIDE ISA 25 contains a low amount of mineral oil which has been optimized to give high immune response and very few local reactions in pigs and cattle.
Experimental results show that these new adjuvants are safe, efficient and suitable to prepare fluid and stable vaccines. The wide range of these adjuvants allows to choose the more suitable product as a function of the antigens and animals. Specific pathogen free Chinchilla rabbits were vaccinated twice with the bovine ringworm vaccine LTF-130 containing live microconidia from an attenuated strain of Trichophyton verrucosum (Biovet Production A/S, Overhaila, Norway). Blood samples were collected at different intervals post vaccination. The antibody response in vaccinated and control rabbits was assessed by an enzyme-linked immunosorbent assay, while the cellular response was assessed by a lymphocyte stimulation test and a skin test. A soluble antigen prepared from microconidia of the vaccine strain, was used in all the tests employed. To assess protection vaccinated and control rabbits were challenged 4 weeks after the second vaccination with a pathogenic strain of T. verrucosum.
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Vaccination of rabbits with a T. verrucosum vaccine elicited a specific immune response demonstrated in both cellular tests and the antibody assay. When challenged, the vaccinated animals were protected against severe ringworm symptoms. In this respect, cellular immunity is considered most important. 
School of Veterinary Scicnces, University of Buenos Aires, Buenos Aires, Argentina
The presence of cell mediated reactions and their importance in protection against viral challenge were studied in vaccinated cattle. A total of 190 young virgin animals from discase free areas was divided in 3 groups: control (C), non vaccinated; vaccinated with one dose of hydroxy-saponined comercial vaccine (HS); and vaccinated with one dose of oil emulsified comercial vaccine (OE). FMDV induced lymphocyte prolipheration, cell migration inhibition and growth factor (IL2?) production were studied in their peripheral mononuclear cells, either 28 (HS group) or 60 (OE) days after primo-vaccination. The same day, cattle were challenged with 104 infective doses of FMDV; 7 days later all animals were retested by the same techniques. All C animals gave consistently negative tests. By migration inhibition, 30 % (24/74) of all vaccinated animals gave positive responses. Only 2 out of 37 showed FMDV induced IL2 production. By prolypheration tests, 4 out of 49 showed stimulation index (SI) _>2, but many animals showed negative SI. Nevertheless, mean SI were significantly higher in the OE group than in C or HS groups. ConA stimulation also gave higher SI in OE than in C or I-IS. No correlation could be seen between positive reactions and protection against challenge. When animals were rctested 7 days after challenge, no further changes could be seen by any technique, neither in protected animals, nor in clinically ill animals, whether or not previously vaccinated. Our data show that one dose of FMDV vaccine may induce cellular immune reactions in some but not all cattle, but these reactions, when present, are always very low and do not correlate with protection. Furthermore, infection with live virus, whether or not leading to clinical disase, does not induce, at least in 7 days, positivization or increase in cell mediated immune reactions. The piliated bacterin vaccines were adjuvanted in equal volume of aluminium hydroxide gel (of 2% cc), or oil (Marcoi-52). The pilus extracts were adjuvanted with aluminium hydroxide, with oil or with ISCOM (Immuno Stimulating Complex).
Results of immunization studies on pilated bacterin indicated an immunosuppressive activity of the oil adjuvanted bacterin in terms of anti pilus titres as compared to aluminium adjuvanted bacterins. These latter bacerins ("Coli 4-P") reduced death losses due to diarrhea of piglets under 10 days by 35-80% in 3 herds tested. In the pilus extract category, ISCOM proved to be the most efficient in terms of titres produced by pilus protein used. ISCOMS did not induce local reaction. The effect of vaccination upon cell counts in blood and milk was tested in a trial with 42 lactating ewes. An experimental vaccine against Staphylococcus aureus mastitis consisting of inactivated S. aureus bacteria cells, S. aureus toxoid and a mineral oil as adjuvant was used. The animals were randomly arranged in five groups and injected twice with an interval of 2-3 weeks. Groups 1 and 2 were injected with vaccine in the supramammary subcutaneous tissue and in the neck, respectively. Groups 3 and 4 were injected with the mineral oil component of the vaccine on the same injection sites. A fifth group of control animals were not injected. Blood and milk samples were taken at the day of injection, the day after and 7 day after. Bovine serum albumin (BSA) was dclivered to mice from matrix systems (pellets) and from osmotic pumps (Alzet R, model 2002) and by injection. The matrix systems were prepared from cholesterol (C) alone and from different ratios of C mixed with hydrogenated egg lecithin (PC). Antigens were given either in pulses or as sustained dclivcry for up to 3 months, and as an initial burst followed by sustaincd dclivery (for 7 months). Murine serum antibodies were measured by enzyme-linked immunosorbent assay (ELISA) for up to one year. The immunogenicity of BSA, delivered by some sustained methods and by some burst-sustained methods, whcn measured as anti-BSA antibodies in mice, was either as effective or more effective than injections (up to three) of same dose of BSA. Tolerance was not induced by sustained delivery of antigen. Several of the matrix systems testcd were bioerodible. We studied FPV DNA recombination involved in the generation of recombinant (FPV (rFPV) vaccines. A p7.5k/fl gal gene construct, cloned adjacent to the FPV tk gene was used as a marker to identify the rFPV products of recombination as "blue" plaques. The proportion of rFPV increased linearly from 0.73 to 6.2 per 1,000 as the cumulative length of homologous sequences increased from 0.73 to 4.5 kb. Two approaches using a second reporter gene, (NDV HN), were developed to differentiate between single or double crossover events. In one, the HN gene was cloned into the FPV tk sequences along with the fl-gal gene in an adjacent region. A single crossover FPV DNA would generate blue plaques expressing HN and subsequent intramolecular recombination would result in excision of the fl-gal gene and generation of white plaque. In a second approach, a double crossover between rFPV DNA containing a stably expr6ssed fl-gal gene cloned into the tk gene (blue plaque) and plasmid DNA containing the HN gene flanked by tk sequences would allow replacement of the fl-gal gene with the HN gene to generate a white plaque. In both cases stable rFPV were generated containing the HN sequences but lacking the fl-gal or other bacterial DNA. We feel either of these approaches would simplify the generation of rFPV for development of novel avian vaccines. The subunit of avian influenza virus (AIV) consisting of nucleoprotein with residual hemagglutinin (NP-HA) was incorporated into immunostimulating complex (ISCOM). The immune response of turkeys vaccinated with NP-HA ISCOM was measured by enzyme-linked immunosorbent assay (ELISA) and antigen-specific lymphocyte stimulation assay (cell-mediated immune response). The protective efficacy to homologous and heterologous and challenge was determined by virus titers in the lungs and trachea. The immune response was found to correlate with type specific cross protection observed following heterologous challenge. It is well established that, compared with adult sheep, immature sheep (less than 12 months old) generally mount weaker immune responses to vaccines and experimental antigens and are more susceptible to many infectious diseases. Our objective is to obtain an understanding of the mechanism responsible for this immunological hyporesponsiveness. Weaner labs immunised systemically with killed Brucella abortus cells developed significantly lower anti-B.abortus lipopolysaccharide (LPS) antibody levels than adult sheep. This phenomenon was independent of the dose of antigen given. When dextran sulphate was used as adjuvant there were still significant differences in anti-LPS responses between weaners and adults. When Quil A was used as an adjuvant, however, the responss of weaners and adults were not significantly different. Because bacterial LPS is a "T-independent ~ antigen these data shed light on the mechanism responsible for hyporesponsiveness. The standard immunization protocol for cats in the United States consists of vaccination against disease associated with rabies, feline rhinotracheitis, feline calici, and feline panleukopenia viruses. Purity, safety, potency, and efficacy standards for vaccines directed at these agents have been in existence for some time and are formally promulgated in Title 9, Code of Federal Regulations. Such is not the case, however, for vaccines against some other organisms which have been identified as significant agents of feline disease and to which interest is increasingly being paid. While continue to be refined, licensing requirements for vaccines against three of these organisms of increasing interest-feline leukemia virus, feline immunodeficiency virus, and feline infectious peritonitis virus-have been developed and are discussed in this presentation. Recombinant rinderpest vaccine (RRV) constructed by inserting rinderpest virus (RV) H gene into attenuated vaccinia virus, LC16mO strain, was subcutaneously inoculated to cattle. These animals developed both antibodies to RV and vaccinia virus without showing any fever or skin reaction. All the animals were completely protected against the challenge by virulent RV. Two groups of controls, contact controls kept in the same pen with the vaccinated cattle and those kept in the separate pen developed fatal disease indicating effectiveness as well as the absence of contact transmission of RRV.
